Cargando…

Advances in Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is one of the most important side effects of glucocorticoid use, as it leads to an increased risk of fractures. Recently, many published studies have focused on the cellular and molecular mechanisms of bone metabolism, the pathophysiology of GIOP, and the i...

Descripción completa

Detalles Bibliográficos
Autores principales: den Uyl, Debby, Bultink, Irene E. M., Lems, Willem F.
Formato: Texto
Lenguaje:English
Publicado: Current Science Inc. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092927/
https://www.ncbi.nlm.nih.gov/pubmed/21365209
http://dx.doi.org/10.1007/s11926-011-0173-y
_version_ 1782203411082510336
author den Uyl, Debby
Bultink, Irene E. M.
Lems, Willem F.
author_facet den Uyl, Debby
Bultink, Irene E. M.
Lems, Willem F.
author_sort den Uyl, Debby
collection PubMed
description Glucocorticoid-induced osteoporosis (GIOP) is one of the most important side effects of glucocorticoid use, as it leads to an increased risk of fractures. Recently, many published studies have focused on the cellular and molecular mechanisms of bone metabolism, the pathophysiology of GIOP, and the intervention options to prevent GIOP. In this review, recent advances in GIOP are summarized, particularly recent progress in our understanding of the mechanisms of GIOP resulting in improved insight that might result in the development of new treatment options in the near future.
format Text
id pubmed-3092927
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Current Science Inc.
record_format MEDLINE/PubMed
spelling pubmed-30929272011-06-07 Advances in Glucocorticoid-Induced Osteoporosis den Uyl, Debby Bultink, Irene E. M. Lems, Willem F. Curr Rheumatol Rep Article Glucocorticoid-induced osteoporosis (GIOP) is one of the most important side effects of glucocorticoid use, as it leads to an increased risk of fractures. Recently, many published studies have focused on the cellular and molecular mechanisms of bone metabolism, the pathophysiology of GIOP, and the intervention options to prevent GIOP. In this review, recent advances in GIOP are summarized, particularly recent progress in our understanding of the mechanisms of GIOP resulting in improved insight that might result in the development of new treatment options in the near future. Current Science Inc. 2011-03-02 2011 /pmc/articles/PMC3092927/ /pubmed/21365209 http://dx.doi.org/10.1007/s11926-011-0173-y Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
den Uyl, Debby
Bultink, Irene E. M.
Lems, Willem F.
Advances in Glucocorticoid-Induced Osteoporosis
title Advances in Glucocorticoid-Induced Osteoporosis
title_full Advances in Glucocorticoid-Induced Osteoporosis
title_fullStr Advances in Glucocorticoid-Induced Osteoporosis
title_full_unstemmed Advances in Glucocorticoid-Induced Osteoporosis
title_short Advances in Glucocorticoid-Induced Osteoporosis
title_sort advances in glucocorticoid-induced osteoporosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092927/
https://www.ncbi.nlm.nih.gov/pubmed/21365209
http://dx.doi.org/10.1007/s11926-011-0173-y
work_keys_str_mv AT denuyldebby advancesinglucocorticoidinducedosteoporosis
AT bultinkireneem advancesinglucocorticoidinducedosteoporosis
AT lemswillemf advancesinglucocorticoidinducedosteoporosis